- |||||||||| Ibrance (palbociclib) / Pfizer, ganitumab (AMG 479) / Takeda, ImmunityBio
Trial termination: Palbociclib + Ganitumab In Ewing Sarcoma (clinicaltrials.gov) - Jul 17, 2024
P2, N=10, Terminated,
Trial primary completion date: Oct 2024 --> May 2024 Completed --> Terminated; The study closed early due to discontinuation of ganitumab supply.
- |||||||||| Simulect (basiliximab) / Novartis, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion date, Trial initiation date, Trial primary completion date: ONSET: 1 vs 7 RATG Infusions in Renal Transplantation (clinicaltrials.gov) - Jul 17, 2024
P=N/A, N=75, Not yet recruiting,
Initiation date: Nov 2024 --> Jul 2024 Trial completion date: Jun 2025 --> Sep 2025 | Initiation date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2025 --> Sep 2025
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Trial completion date, Trial initiation date, Trial primary completion date, Tumor mutational burden: REPRINT: Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (clinicaltrials.gov) - Jul 17, 2024
P2, N=23, Not yet recruiting,
Trial completion date: Nov 2029 --> May 2032 | Trial primary completion date: Nov 2026 --> May 2029 Trial completion date: May 2028 --> Nov 2028 | Initiation date: May 2024 --> Nov 2024 | Trial primary completion date: Oct 2026 --> Apr 2027
- |||||||||| Rituxan (rituximab) / Roche
Trial completion date, Trial initiation date, Trial primary completion date: PROMENADE: An Outcome Analysis of Primary Membranous Nephropathy (clinicaltrials.gov) - Jul 17, 2024
P=N/A, N=500, Not yet recruiting,
Trial completion date: May 2028 --> Nov 2028 | Initiation date: May 2024 --> Nov 2024 | Trial primary completion date: Oct 2026 --> Apr 2027 Trial completion date: May 2029 --> Sep 2029 | Initiation date: May 2024 --> Sep 2024 | Trial primary completion date: May 2029 --> Sep 2029
- |||||||||| KN5501 / Nanjing Enricnk Biotech
Trial completion date, Trial initiation date, Trial primary completion date: An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 17, 2024
P1, N=12, Recruiting,
Trial completion date: May 2029 --> Sep 2029 | Initiation date: May 2024 --> Sep 2024 | Trial primary completion date: May 2029 --> Sep 2029 Trial completion date: Aug 2026 --> Aug 2025 | Initiation date: Jul 2024 --> Aug 2023 | Trial primary completion date: Aug 2025 --> Aug 2024
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), MB12 (pembrolizumab biosimilar) / Grupo Insud
Trial completion date, Trial primary completion date, Metastases: MB12-C-01-22: Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda (clinicaltrials.gov) - Jul 17, 2024
P3, N=174, Recruiting,
Trial completion date: Aug 2026 --> Aug 2025 | Initiation date: Jul 2024 --> Aug 2023 | Trial primary completion date: Aug 2025 --> Aug 2024 Trial completion date: Dec 2025 --> Dec 2024 | Trial primary completion date: Aug 2025 --> Aug 2024
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial completion date, Trial primary completion date: Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (clinicaltrials.gov) - Jul 17, 2024
P=N/A, N=368, Active, not recruiting,
Trial completion date: Nov 2025 --> Mar 2026 Trial completion date: Oct 2025 --> Dec 2024 | Trial primary completion date: Oct 2025 --> Dec 2024
- |||||||||| sigvotatug vedotin (PF-08046047) / Pfizer
Trial completion date, Metastases: SGNB6A-001: A Study of SGN-B6A in Advanced Solid Tumors (clinicaltrials.gov) - Jul 17, 2024
P1, N=824, Recruiting,
Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Sep 2025 Trial completion date: Oct 2028 --> Feb 2028
- |||||||||| inobrodib (CCS1477) / CellCentric
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study to Evaluate CCS1477 in Advanced Tumours (clinicaltrials.gov) - Jul 17, 2024
P1/2, N=350, Recruiting,
Trial completion date: Apr 2024 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Mar 2025 Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Combination therapy, Metastases: RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers (clinicaltrials.gov) - Jul 17, 2024
P1, N=11, Active, not recruiting,
Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024 Trial completion date: Jul 2024 --> Jul 2025
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors. (Pubmed Central) - Jul 17, 2024
Despite the low histological grade and radical surgical treatment of the tumor at primary manifestation, the disease had aggressive clinical course and the response to BRAF/MEK targeted therapy at recurrence was complete but nondurable. Empirical use of pembrolizumab provided no unambiguous evidence on the clinical relevance of immunotherapy in protein kinase -rearranged spindle cell tumors.
- |||||||||| Rituxan (rituximab) / Roche
Clinical, Review, Journal, Head-to-Head: Head-to-head studies on connective tissue diseases and vasculitides (Pubmed Central) - Jul 17, 2024
In recent H2H trials rituximab could be established as induction and maintenance therapy for AAV, which has now been incorporated into current treatment guidelines. Further comparative trials will be necessary in order to select the most effective and safest treatment for every patient, in the sense of personalized medicine.
- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Advances in biology, diagnosis and treatment of DLBCL. (Pubmed Central) - Jul 17, 2024
In recent decades, the improvement of diagnostic levels has led to a refinement classification of DLBCL and the development of new therapeutic approaches. The objective of this review was to summarize the latest studies examining genetic lesions and therapies for DLBCL.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Cytokine release syndrome: Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy. (Pubmed Central) - Jul 17, 2024
It is still difficult to distinguish CRS from other dangerous, acute and life-threatening medical disorders.We present a case of delayed grade 4 CRS following treatment of lung adenocarcinoma with ipilimumab plus nivolumab that warranted intensive care level treatment with abundant fluid resuscitation, two-tire vasopressor support, high-flow nasal oxygenation, corticosteroids in high dosages, as well as sustained low-efficiency daily diafiltration with CytoSorb hemadsorption and tocilizumab. Initial treatment of presumed septic shock of unknown origin did not yield results.After initiation of corticosteroids and particularly CytoSorb hemadsorption and tocilizumab, prompt clinical and laboratory improvement was observed.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, Metastases: Successful treatment of aggressive metastatic sebaceous carcinoma with pembrolizumab. (Pubmed Central) - Jul 17, 2024
Initial treatment of presumed septic shock of unknown origin did not yield results.After initiation of corticosteroids and particularly CytoSorb hemadsorption and tocilizumab, prompt clinical and laboratory improvement was observed. No abstract available
- |||||||||| Rituxan (rituximab) / Roche
Journal: A Case of Secondary Autoimmune Hemolytic Anemia Successfully Treated With Rituximab. (Pubmed Central) - Jul 17, 2024
Rituximab is historically only effective in primary cold AIHA, but it appeared to elicit significant clinical improvement with our use in secondary cold AIHA. While there have been a handful of studies demonstrating its successful use in secondary cold AIHA, we propose that this medication be further studied to prevent the significant morbidity and mortality associated with the disease.
- |||||||||| NHWD-870 / Ningbo Wenda Pharma, Opdivo (nivolumab) / BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Primary thyroid nuclear protein in testis carcinoma: a case report and literature review. (Pubmed Central) - Jul 17, 2024
Gene rearrangement detection is also helpful for diagnosis and treatment. At present, surgery and radiation are still first choices for NC, and advances in targeted immunotherapy such as bromodomain and end motif inhibitors (BETi) may bring better treatment options to patients.
- |||||||||| Opdivo (nivolumab) / BMS
Review, Journal: Contemporary management of mesothelioma. (Pubmed Central) - Jul 17, 2024
In the second-line setting, single-agent nivolumab has been shown to extend survival and is now available for routine use in some regions, while second-line chemotherapy has no proven role and opportunities for clinical trials should be maximised in relapsed disease...The observation of improving outcomes in centres that have adopted this service model emphasises the importance of high-quality diagnostics and equitable access to therapies and trials. Novel therapies targeting a range of aberrations are being evaluated; however, a better understanding of the molecular drivers and their associated vulnerabilities is required to identify and prioritise treatment targets.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker: Cancer of Unknown Primary: When Imaging, Pathology, and Molecular Biology Do Not Match. (Pubmed Central) - Jul 17, 2024
The patient had a drastic improvement in dyspnea, weight gain, and was able to return to work. This report describes a case in which immunohistochemistry and molecular profiling did not identify the tissue of origin and highlights the importance of a multidisciplinary team to reach a diagnosis and guide treatment without delaying patient care in patients with these diagnoses.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Journal: Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China. (Pubmed Central) - Jul 17, 2024
After his pulmonary infection was relieved by comprehensive treatment, the patient received first-line treatment with durvalumab plus etoposide and carboplatin...He was diagnosed with immune-induced pneumonia and treated with methylprednisolone, cefoperazone, and sulbactam, followed by oxygen and pirfenidone...Immune-related pneumonitis induced by PD-L1 inhibitors is rare but life-threatening. Infection should be ruled out before starting immunotherapy.
- |||||||||| Darzalex (daratumumab) / J&J, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
Retrospective data, Review, Journal: Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review. (Pubmed Central) - Jul 17, 2024
The literature review returned 23 eligible papers on PRCA treatment, with high success rate using plasma-exchange (PEX) and immunoadsorption procedures, daratumumab, and eltrombopag...All patients with PRCA had received rhEPO and transfusion support and 20 patients received additional treatments like PEX, rituximab, and more recently daratumumab...The overall response rate in our cohort was 75%, with significantly better survival (94.4% vs. 16.7%) and lower transplant-related mortality (6.3% vs. 80%) for PRCA responders. Standardized guidelines on when and how to treat PRCA are necessary because the current treatment is controversial among centers.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Pityriasis Lichenoides et Varioliformis Acuta Developing during Pembrolizumab Treatment for Bladder Cancer. (Pubmed Central) - Jul 17, 2024
From these results, he was diagnosed with PLEVA, which might be classified as a lichenoid eruption, especially based on the histological findings. We hypothesize that the anti-PD-1 antibody might lead to epidermal necrosis by amplifying the expression of cytolytic molecules such as granzyme B in CD8+ T cells.
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Ocrevus (ocrelizumab) / Roche
Review, Journal: Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review. (Pubmed Central) - Jul 17, 2024
Recommended options include integrin antagonist therapy including natalizumab as well as anti-CD20 monoclonal antibodies like, ocrelizumab, rituximab, ofatumumab, and ublituximab...A chest CT scan revealed multifocal ground-glass opacities suggestive of organizing pneumonia, likely secondary to ocrelizumab. The patient's condition improved with high-dose corticosteroids, underscoring the importance of vigilance for extremely rare ocrelizumab-associated pulmonary side effects and the need for prompt, appropriate intervention.
- |||||||||| BMS-986012 / BMS, Opdivo (nivolumab) / BMS
Enrollment closed, Combination therapy: CA001-050: A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - Jul 17, 2024
P2, N=120, Active, not recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Sep 2025 --> Nov 2024 Recruiting --> Active, not recruiting
|
